Infectious disease test kit EIA6150

IgGSARS-COV-2serum

The DRG SARS-CoV-2 (RBD) IgG† is a solid phase enzyme-linked immunosorbent assay (ELISA). Microtiter wells as a solid phase are coated with recombinant Receptor-Binding-Domaine (RBD) of the Spike Protein S1 of SARS-CoV-2. Diluted patient specimens and ready-for-use Standards and Controls are pipetted into these wells. During incubation, SARS-CoV-2 (RBD)† specific antibodies of standards/controls and positive specimens are bound to the immobilized RBD antigen. After a washing step to remove unbound sample and control material, Enzyme conjugate, which is horseradish peroxidase conjugated anti-human IgG antibodies is dispensed into the wells. During a second incubation, this anti-IgG conjugate binds specifically to human IgG antibodies resulting in the formation of enzyme-linked immune complexes. After a washing step to remove all unbound substances, the solid phase is incubated with the substrate solution. The colorimetric reaction is stopped by addition of stop solution, and optical density (OD) of the resulting yellow product is measured. The intensity of color is proportional to the concentration of the analyte in the sample. A standard curve is constructed by plotting OD values against concentrations of standards, and concentrations of unknown samples are determined using this standard curve. † – “Due to Regulatory Restrictions, sales of these products may not be available in your territory. The SARS kits are CE/IVD in the EU” CE Y # of Tests 96 wells Range 0.046 - 2.348 DU/mL Sensitivity 0.046 DU/mL Storage Conditions 2�C - 8�C